Eagle Pharmaceuticals Inc (EGRX) — Cash Flow-to-Debt Ratio
Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow-to-Debt Ratio of 0.00x as of June 2023, meaning its operating cash flow of $-126.00K could theoretically repay 0% of its total liabilities ($152.78 Million) in one year. Check Eagle Pharmaceuticals Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eagle Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2022)
Historical debt coverage capacity for Eagle Pharmaceuticals Inc across 11 annual periods. Also explore Eagle Pharmaceuticals Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Eagle Pharmaceuticals Inc (2012–2022)
Year-by-year debt coverage analysis for Eagle Pharmaceuticals Inc. For market capitalisation and broader financial context, see EGRX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2022 | 0.18x | $30.80 Million | $172.60 Million | ▼ -51.1% |
| 2021 | 0.37x | $28.22 Million | $77.28 Million | ▼ -50.4% |
| 2020 | 0.74x | $49.50 Million | $67.18 Million | ▼ -0.8% |
| 2019 | 0.74x | $55.99 Million | $75.38 Million | ▲ +10.4% |
| 2018 | 0.67x | $52.38 Million | $77.84 Million | ▲ +3.8% |
| 2017 | 0.65x | $58.92 Million | $90.92 Million | ▼ -24.1% |
| 2016 | 0.85x | $53.21 Million | $62.34 Million | ▲ +400.9% |
| 2015 | -0.28x | $-9.72 Million | $34.26 Million | ▲ +58.4% |
| 2014 | -0.68x | $-13.84 Million | $20.32 Million | ▼ -86.0% |
| 2013 | -0.37x | $-5.88 Million | $16.05 Million | ▲ +49.3% |
| 2012 | -0.72x | $-15.55 Million | $21.54 Million | — |